Abstract
Emerging preclinical autism research has shown the therapeutic promise of pharmacological inhibitors for epigenetic enzymes, such as histone deacetylases (HDAC), euchromatic histone methyltransferases (EHMT), and lysine-specific histone demethylase 1A (LSD1). These interventions restore gene expression, synaptic function, and behavioral performance in autism models, highlighting a new strategy for autism treatment.
Keywords:
autism; epigenetics; histone modification; social deficits; synaptic.
Copyright © 2024 Elsevier Ltd. All rights reserved.
MeSH terms
-
Animals
-
Autistic Disorder* / drug therapy
-
Autistic Disorder* / genetics
-
Epigenesis, Genetic*
-
Histone Deacetylase Inhibitors / pharmacology
-
Histone Deacetylase Inhibitors / therapeutic use
-
Histone Deacetylases / genetics
-
Histone Deacetylases / metabolism
-
Histone Demethylases* / antagonists & inhibitors
-
Histone Demethylases* / genetics
-
Histone Demethylases* / metabolism
-
Histone-Lysine N-Methyltransferase / antagonists & inhibitors
-
Histone-Lysine N-Methyltransferase / genetics
-
Histone-Lysine N-Methyltransferase / metabolism
-
Humans
Substances
-
Histone Demethylases
-
Histone Deacetylase Inhibitors
-
Histone-Lysine N-Methyltransferase
-
Histone Deacetylases
-
KDM1A protein, human